TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to deliver. Learn more on TGTX stock here.
Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...
ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a clinical-stage biopharmaceutical company with a current market capitalization of $52 million, reported at the Hawaiian Eye and Retina 2025 ...
Outlook Therapeutics (OTLK) announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting being held January ...
NDAQ:ATOS) Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 ...
The Nigerian economy is on track for a robust 4.17% growth in 2025, a significant improvement from the 3.36% recorded in 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback